Evidence map›Paper›PMID 35734926›Full record

ArticleHaematologica2023

In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.

Keren Isaev, Ting Liu, Mehran Bakhtiari, Kit Tong, Rashmi Goswami, Bernard Lam, Ilinca Lungu, Paul M Krzyzanowski, Amit Oza, Neesha Dhani and 3 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Keren IsaevPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Ting LiuPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Mehran BakhtiariPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Kit TongPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Rashmi GoswamiSunnybrook Health Sciences Centre, Toronto, ON.
Bernard LamOntario Institute for Cancer Research, Toronto, ON.
Ilinca LunguOntario Institute for Cancer Research, Toronto, ON.
Paul M KrzyzanowskiOntario Institute for Cancer Research, Toronto, ON.
Amit OzaPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Neesha DhaniPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Anca PricaPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Michael CrumpPrincess Margaret Cancer Centre - University Health Network, Toronto, ON.
Robert KridelPrincess Margaret Cancer Centre - University Health Network, Toronto, ON. robert.kridel@uhn.ca.
Princess Margaret Cancer Centre · CAUniversity Health Network · CAOntario Institute for Cancer Research · CAHealth Sciences Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by applying whole-genome sequencing to spatially separated tumor samples harvested at the time of autopsy (n=24) and/or diagnosis (n=3) in three patients presenting with refractory B-cell non-Hodgkin lymphoma. Through deconvolution of bulk samples into clonal mixtures and inference of phylogenetic trees, we found evidence that polyclonal seeding underlies tumor dissemination in lymphoma. We identify mutation signatures associated with ancestral and descendant clones. In our series of patients with highly refractory lymphoma, the determinants of resistance were often harbored by founding clones, although there was also evidence of positive selection of driver mutations, likely under the influence of therapy. Lastly, we show that circulating tumor DNA is suitable for the detection of ancestral mutations but may miss a significant proportion of private mutations that can be detected in tissue. Our study clearly shows the existence of intricate patterns of regional and anatomical evolution that can only be disentangled through multi-regional tumor tissue profiling.

Indexed as

Circulating Tumor DNALymphoma, B-CellAutopsyHumansMutationPhylogenyCirculating Tumor DNA

Identifiers

PMID35734926
PMCPMC9827161
OpenAlexW4283311968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.